利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.033 秒)

    Adam12, A Novel Marker For Abnormal Cell Function
    3.
    发明申请
    Adam12, A Novel Marker For Abnormal Cell Function 审中-公开
    Adam12，一种用于异常细胞功能的新型标记

    公开(公告)号：US20120149040A1

    公开(公告)日：2012-06-14

    申请号：US13356801

    申请日：2012-01-24

    申请人： Ulla M. Wewer ,  Bent Norgaard-Pedersen ,  Michael Christiansen ,  Jennie Laigaard ,  Camilla Fröhlich ,  Kevin Spencer

    发明人： Ulla M. Wewer ,  Bent Norgaard-Pedersen ,  Michael Christiansen ,  Jennie Laigaard ,  Camilla Fröhlich ,  Kevin Spencer

    IPC分类号： G01N33/573 ,  G01N21/64 ,  C12Q1/68 ,  C12Q1/37

    CPC分类号： G01N33/689 ,  G01N2333/4745 ,  G01N2333/96486 ,  G01N2800/36 ,  G01N2800/368 ,  G01N2800/385 ,  G01N2800/387 ,  Y10T436/143333

    摘要： The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum. The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and/or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.

    摘要翻译： 本发明提供了用于提供异常细胞功能指示的方法，测定和试剂盒。 本发明人描述了ADAM12作为异常细胞功能的总体标准，本发明人首次证明ADAM12是胎儿染色体病和胎盘功能的重要指标。 具体地说，ADAM12是例如， 唐氏综合征，18三体，先兆子痫，特纳综合征在第一和第二个三个月。 本发明人开发了用于定量血清中ADAM12的酶联免疫吸附测定（ELISA）和时间分辨免疫荧光测定法。 本申请在几个例子中表明，与正常对照相比，胎儿异常和/或不良妊娠结局中ADAM12水平的变化与孕龄相关。 本发明的一个目的是提供现有标记物测试的改进，其显示出降低的假阳性率。

    Chain link attached hook
    4.
    发明申请
    Chain link attached hook 审中-公开
    链条挂钩

    公开(公告)号：US20060237609A1

    公开(公告)日：2006-10-26

    申请号：US11113800

    申请日：2005-04-25

    申请人： Kevin Spencer

    发明人： Kevin Spencer

    IPC分类号： F16B45/00

    CPC分类号： F16B45/00

    摘要： An s-hook is described, which has a loop formed in its mid-section between its two open-end hooks. The loop is formed around one side of the terminal link in a support chain, thereby being permanently but flexibly attached to the chain. The configuration of the s-hook causes it to be pulled out and away from the support structure.

    摘要翻译： 描述了一种s钩，其具有在其两个开口钩之间的中间部分中形成的环。 环路形成在支撑链中的终端连接件的一侧，从而永久地但柔性地附接到链条上。 s钩的构造使其被拉出并远离支撑结构。

    ADAM12, a novel marker for abnormal cell function
    5.
    发明授权
    ADAM12, a novel marker for abnormal cell function 失效
    ADAM12，一种用于异常细胞功能的新型标志物

    公开(公告)号：US07678544B2

    公开(公告)日：2010-03-16

    申请号：US11131952

    申请日：2005-05-18

    申请人： Ulla M. Wewer ,  Bent Nørgaard-Pedersen ,  Michael Christiansen ,  Jennie Laigaard ,  Camilla Fröhlich ,  Kevin Spencer

    发明人： Ulla M. Wewer ,  Bent Nørgaard-Pedersen ,  Michael Christiansen ,  Jennie Laigaard ,  Camilla Fröhlich ,  Kevin Spencer

    IPC分类号： G01N33/53 ,  C07K14/00

    CPC分类号： G01N33/689 ,  G01N2333/4745 ,  G01N2333/96486 ,  G01N2800/36 ,  G01N2800/368 ,  G01N2800/385 ,  G01N2800/387 ,  Y10T436/143333

    摘要： The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function.The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester.The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and/or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.

    摘要翻译： 本发明提供了用于提供异常细胞功能指示的方法，测定和试剂盒。 惊奇地发现，个体中血清ADAM12浓度的变化可用作预测异常细胞功能后的临床结果，并发症和死亡率的预后工具。 本发明人描述了ADAM12作为异常细胞功能的总体标准，本发明人首次证明ADAM12是胎儿染色体病和胎盘功能的重要指标。 具体地说，ADAM12是例如， 唐氏综合征，18三体，先兆子痫，特纳综合征在第一和第二个三个月。 本发明人开发了用于定量血清中ADAM12的酶联免疫吸附测定（ELISA）和时间分辨免疫荧光测定法。 本申请在几个例子中表明，与正常对照相比，胎儿异常和/或不良妊娠结局中ADAM12水平的变化与孕龄相关。 本发明的一个目的是提供现有标记物测试的改进，其显示出降低的假阳性率。

    ADAM12, a novel marker for abnormal cell function
    6.
    发明申请
    ADAM12, a novel marker for abnormal cell function 失效
    ADAM12，一种用于异常细胞功能的新型标志物

    公开(公告)号：US20060134654A1

    公开(公告)日：2006-06-22

    申请号：US11131952

    申请日：2005-05-18

    申请人： Ulla Wewer ,  Bent Norgaard-Pedersen ,  Michael Christiansen ,  Jennie Laigaard ,  Camilla Frohlich ,  Kevin Spencer

    发明人： Ulla Wewer ,  Bent Norgaard-Pedersen ,  Michael Christiansen ,  Jennie Laigaard ,  Camilla Frohlich ,  Kevin Spencer

    IPC分类号： C12Q1/68

    CPC分类号： G01N33/689 ,  G01N2333/4745 ,  G01N2333/96486 ,  G01N2800/36 ,  G01N2800/368 ,  G01N2800/385 ,  G01N2800/387 ,  Y10T436/143333

    摘要： The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum. The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and/or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.

    摘要翻译： 本发明提供了用于提供异常细胞功能指示的方法，测定和试剂盒。 惊奇地发现，个体中血清ADAM12浓度的变化可用作预测异常细胞功能后的临床结果，并发症和死亡率的预后工具。 本发明人描述了ADAM12作为异常细胞功能的总体标准，本发明人首次证明ADAM12是胎儿染色体病和胎盘功能的重要指标。 具体地说，ADAM12是例如， 唐氏综合征，18三体，先兆子痫，特纳综合征在第一和第二个三个月。 本发明人开发了用于定量血清中ADAM12的酶联免疫吸附测定（ELISA）和时间分辨免疫荧光测定法。 本申请在几个例子中表明，与正常对照相比，胎儿异常和/或不良妊娠结局中ADAM12水平的变化与孕龄相关。 本发明的一个目的是提供现有标记物测试的改进，其显示出降低的假阳性率。